Patents by Inventor Andrew DORR

Andrew DORR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoconjugates targeting CD46 and methods of use thereof
    Patent number: 12144888
    Abstract: Disclosed herein are immunoconjugates comprising a CD46 binding domain and effector agent. Further provided herein are methods of treating cancer comprising administering to a subject having cancer a pharmaceutical composition comprising immunoconjugates comprising a CD46 binding domain and effector agent.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: November 19, 2024
    Assignee: Fortis Therapeutics, Inc.
    Inventors: Marc Nasoff, Andrew Dorr
  • COMBINATION THERAPY WITH FOR46 FOR CANCER
    Publication number: 20240058464
    Abstract: Disclosed herein are methods of treating cancer. Some such methods include administration of a first anti-cancer agent that increases CD46 expression on the surface of a cancer cell. Some embodiments include administration of a second anti-cancer agent that binds CD46. The second anti-cancer agent may include an immunoconjugate comprising a CD46 binding domain and effector agent.
    Type: Application
    Filed: January 6, 2022
    Publication date: February 22, 2024
    Applicants: Fortis Therapeutics, Inc., The Regents of the University of California
    Inventors: Bin LIU, Andrew DORR, Jay LICHTER, Marc NASOFF, Leonard POST
  • IMMUNOCONJUGATES TARGETING CD46 AND METHODS OF USE THEREOF
    Publication number: 20230035087
    Abstract: Disclosed herein are immunoconjugates comprising a CD46 binding domain and effector agent. Further provided herein are methods of treating cancer comprising administering to a subject having cancer a pharmaceutical composition comprising immunoconjugates comprising a CD46 binding domain and effector agent.
    Type: Application
    Filed: September 19, 2022
    Publication date: February 2, 2023
    Inventors: Marc NASOFF, Andrew DORR
  • Immunoconjugates targeting CD46 and methods of use thereof
    Patent number: 11484604
    Abstract: Disclosed herein are immunoconjugates comprising a CD46 binding domain and effector agent. Further provided herein are methods of treating cancer comprising administering to a subject having cancer a pharmaceutical composition comprising immunoconjugates comprising a CD46 binding domain and effector agent.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: November 1, 2022
    Assignee: FORTIS THERAPEUTICS, INC.
    Inventors: Marc Nasoff, Andrew Dorr
  • IMMUNOCONJUGATES TARGETING CD46 AND METHODS OF USE THEREOF
    Publication number: 20220331443
    Abstract: Disclosed herein are immunoconjugates comprising a CD46 binding domain and effector agent. Further provided herein are methods of treating cancer comprising administering to a subject having cancer a pharmaceutical composition comprising immunoconjugates comprising a CD46 binding domain and effector agent.
    Type: Application
    Filed: June 28, 2022
    Publication date: October 20, 2022
    Inventors: Marc NASOFF, Andrew DORR
  • IMMUNOCONJUGATES TARGETING CD46 AND METHODS OF USE THEREOF
    Publication number: 20220047712
    Abstract: Disclosed herein are immunoconjugates comprising a CD46 binding domain and effector agent. Further provided herein are methods of treating cancer comprising administering to a subject having cancer a pharmaceutical composition comprising immunoconjugates comprising a CD46 binding domain and effector agent.
    Type: Application
    Filed: August 5, 2021
    Publication date: February 17, 2022
    Inventors: Marc NASOFF, Andrew DORR